Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP) as an epigenetic strategy for treating prostate cancer is mounting.

In a paper published

Read the full 311 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE